Literature DB >> 34089924

Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.

Helen B Simpson1, Edna B Foa2, Michael G Wheaton3, Thea Gallagher2, Marina Gershkovich4, Andrew B Schmidt4, Jonathan D Huppert5, Raphael B Campeas4, Patricia A Imms2, Shawn P Cahill6, Christina DiChiara7, Steven D Tsao7, Anthony C Puliafico4, Daniel Chazin2, Anu Asnaani8, Kelly Moore9, Jeremy Tyler2, Shari A Steinman10, Arturo Sanchez-LaCay4, Sandy Capaldi2, Ivar Snorrason11, Elizabeth Turk-Karan2, Donna Vermes4, Eyal Kalanthroff5, Anthony Pinto12, Chang-Gyu Hahn2, Bin Xu13, Page E Van Meter4, Martha Katechis4, Jennifer Scodes14, Yuanjia Wang15.   

Abstract

Practice guidelines for adults with obsessive-compulsive disorder (OCD) recommend augmenting serotonin reuptake inhibitors (SRIs) with exposure and ritual prevention (EX/RP). However, fewer than half of patients remit after a standard 17-session EX/RP course. We studied whether extending the course increased overall remission rates and which patient factors predicted remission. Participants were 137 adults with clinically significant OCD (Yale-Brown Obsessive Compulsive Scale [Y-BOCS] score ≥18) despite an adequate SRI trial (≥12 weeks). Continuing their SRI, patients received 17 sessions of twice-weekly EX/RP (standard course). Patients who did not remit (Y-BOCS ≤12) received up to 8 additional sessions (extended course). Of 137 entrants, 123 completed treatment: 49 (35.8%) remitted with the standard course and another 46 (33.6%) with the extended course. Poorer patient homework adherence, more Obsessive-Compulsive Personality Disorder (OCPD) traits, and the Brain-Derived Neurotrophic Factor (BDNF) Val66MET genotype were associated with lower odds of standard course remission. Only homework adherence differentiated non-remitters from extended course remitters. Extending the EX/RP course from 17 to 25 sessions enabled many (69.3%) OCD patients on SRIs to achieve remission. Although behavioral (patient homework adherence), psychological (OCPD traits), and biological (BDNF genotype) factors influenced odds of EX/RP remission, homework adherence was the most potent patient factor overall.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CBT; Cognitive-behavioral therapy; EX/RP; Exposure and ritual prevention; OCD; Obsessive-compulsive disorder

Mesh:

Substances:

Year:  2021        PMID: 34089924      PMCID: PMC8241471          DOI: 10.1016/j.brat.2021.103890

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  41 in total

1.  A short form of the metacognitions questionnaire: properties of the MCQ-30.

Authors:  Adrian Wells; Sam Cartwright-Hatton
Journal:  Behav Res Ther       Date:  2004-04

2.  Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder.

Authors:  David Mataix-Cols; Lorena Fernández de la Cruz; Ashley E Nordsletten; Fabian Lenhard; Kayoko Isomura; Helen Blair Simpson
Journal:  World Psychiatry       Date:  2016-02       Impact factor: 49.548

3.  Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?

Authors:  Michael G Wheaton; David Rosenfield; Edna B Foa; H Blair Simpson
Journal:  J Consult Clin Psychol       Date:  2015-05-25

4.  A new initiative on precision medicine.

Authors:  Francis S Collins; Harold Varmus
Journal:  N Engl J Med       Date:  2015-01-30       Impact factor: 91.245

5.  Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes well?

Authors:  Michael G Wheaton; Hanga Galfalvy; Shari A Steinman; Melanie M Wall; Edna B Foa; H Blair Simpson
Journal:  Behav Res Ther       Date:  2016-07-29

6.  Patient adherence to cognitive-behavioral therapy predicts long-term outcome in obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Sue M Marcus; Allan Zuckoff; Martin Franklin; Edna B Foa
Journal:  J Clin Psychiatry       Date:  2012-09       Impact factor: 4.384

Review 7.  Minority participation in randomized controlled trials for obsessive-compulsive disorder.

Authors:  Monnica Williams; Mark Powers; Yeo-Gin Yun; Edna Foa
Journal:  J Anxiety Disord       Date:  2010-03

8.  Genetic gating of human fear learning and extinction: possible implications for gene-environment interaction in anxiety disorder.

Authors:  Tina B Lonsdorf; Almut I Weike; Pernilla Nikamo; Martin Schalling; Alfons O Hamm; Arne Ohman
Journal:  Psychol Sci       Date:  2009-01-23

9.  The Yale-Brown Obsessive Compulsive Scale. II. Validity.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; P Delgado; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

10.  The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder.

Authors:  Tina B Lonsdorf; Christian Rück; Jan Bergström; Gerhard Andersson; Arne Ohman; Nils Lindefors; Martin Schalling
Journal:  BMC Psychiatry       Date:  2010-11-26       Impact factor: 3.630

View more
  1 in total

1.  Year of Zoom in a Year of Doom: Lessons Learned Delivering ERP Remotely During the COVID-19 Pandemic.

Authors:  Dianne M Hezel; Amy M Rapp; Shannon Glasgow; Gail Cridland; H Blair Simpson
Journal:  Cogn Behav Pract       Date:  2022-02-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.